Back to search results

A Study of Language Interpretation for Breast Cancer Patients

This study is looking at different ways to provide language interpretation for people with breast cancer who speak Spanish or Mandarin and have limited English. It compares three types of remote interpreting: Remote Simultaneous Medical Interpreting (RSMI), Remote Consecutive Medical Interpreting (RCMI), and Remote Consecutive Video Medical Interpreting (RCVI). The goal is to see which method leads to the fewest interpretation errors. You might be able to join if you are at least 18 years old, have breast cancer (Stage II or III), and speak Spanish or Mandarin as your preferred language for healthcare. The study is currently unclear on its recruitment status and plans to enroll about 700 people.

Study design
This is an interventional study with two overlapping phases. Phase 1 is a randomized controlled trial comparing three different interpretation methods, involving about 700 participants.
What's involved
You would be visiting MSK oncology teams for your first or second appointment and agree to have your medical encounter audio-recorded. The study measures interpretation errors for up to 30 days.
Compensation
Not stated in the trial record.
Follow-up
Interpretation errors will be measured for up to 30 days after your appointment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06721065

A Study of Language Interpretation Solutions for People With Breast Cancer

Recruiting
NAAges 18+InterventionalHealth services
Memorial Sloan Kettering Cancer Center
~700 participants
Updated 2026-05-12 on ClinicalTrials.gov
What's tested:Remote Simultaneous Medical Interpreting/RSMIRemote Consecutive Medical Interpreting/RCMIRemote Consecutive Video Medical Interpreting/RCVI

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of interpretation errors
Measured over up to 30 days

Conditions

Breast Cancer
Breast Cancer Stage II
Breast Cancer Stage III

Explore related trials

Breast CarcinomaMalignant Digestive System Neoplasm

Where it's being run

8 sites across 2 states
New York5
New Jersey3

Study leadership

  • Francesca Gany, MD, MS · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Francesca Gany, MD, MS
[email protected]
646-888-8054
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>=18 years (per EMR)
Preferred language for healthcare is Spanish or Mandarin (per self-report)
Limited English Proficient; cannot speak English "very well" (per self-report)
Diagnosis of breast cancer or gastrointestinal (per EMR)
Will be visiting MSK oncology teams for the first or second appointment (per EMR)
Agrees to be audio-recorded (per self-report)
Breast or gastrointestinal cancer provider who sees patients (e.g., breast or gastrointestinal oncologists, advanced practice providers, and/or nurses)
Does not speak Spanish and/or Mandarin; providers who speak one language and not the other may participate (e.g., speaks Spanish but not Mandarin) (per self-report)
Agrees to be audio-record (per self-report) Phase 2 (clinic staff only; patient participants will be drawn from Phase 1)
Is a staff member who works/worked in one of the study clinic sites during the period of Phase 1 RCT study activities
Agrees to be audio-recorded (per self-report)

Exclusion

Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient's care team, or study team)
Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team)
None
None

What this trial measures

  • Number of interpretation errorsup to 30 days

    Via translation and transcription of audio recordings, errors will be determined in the interpretation of medical facts made in each of the RCT arms during Study Visit 1 (post- diagnosis)